NCT00272649View on ClinicalTrials.gov

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

AGS-003

Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)

Trial Locations (10)

14263

Roswell Park Cancer Institute, Buffalo

28204

Carolinas Medical Center/Blumenthal Cancer Center, Charlotte

30322

Emory University, Atlanta

46202

The Indiana University Cancer Center/IUPUI, Indianapolis

80045

Univ. of Colorado Health Science Center - Division of Medical Oncology, Aurora

89135

Nevada Cancer Institute, Las Vegas

90095-7207

UCLA Kidney Cancer Program, Los Angeles

97213-2933

Earle A. Chiles Research Institute, Portland

MG5 2M9

Princess Margaret Hospital, Toronto

H3T 1E2

Jewish General Hospital, Montreal

Sponsors

Lead Sponsor

Argos Therapeutics
All Listed Sponsors
lead

Argos Therapeutics

INDUSTRY

NCT00272649 - Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer | Biotech Hunter | Biotech Hunter